

## Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 9 January 2024

The Extraordinary General Meeting in LIDDS AB (PUBL) ("LIDDS") was held on 9 January 2024 and in particular the following decisions were resolved.

- The Extraordinary General Meeting resolved to elect Daniel Lifveredson, Torbjörn Browall and Lars-Inge Sjöqvist as ordinary board members, and Bengt Viterius as deputy board member. Daniel Lifveredson was elected as Chairman of the Board.
- The Extraordinary General Meeting resolved to approve a fee to the Board of Directors of a total of SEK 225,000, of which SEK 112,500 is to be paid to the Chairman of the Board and SEK 56,250 to each of the other ordinary Board members.

Notice and complete proposals are available on the Company's website: <https://liddspharma.com/investors/#corporate-governance> North Growth Market.

**For additional information, please contact**

---

Jenni Björnulfson, CEO and CFO  
Phone: +46 (0)70 855 38 05  
E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB

### LIDDS in brief:

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

### Attachments

---

**Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 9 January 2024**